SCHEMBL6772044

SCHEMBL6772044

C#CCc1cccc2c1nc(C#Cc1ccccc1)n2-c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
ALDH1A1 P00352 2/20 0.30
HPGD P15428 2/20 0.30
MAPT P10636 1/20 0.30
ALOX12 P18054 1/20 0.30
PTGS2 P35354 1/20 0.30
GRM5 P41594 2/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8548657 0.72 MAPK1 (0.53) ALDH1A1HPGDMAPK1HTTKDM4E
SCHEMBL18510272 0.62 PTGS2 (0.38) ADORA3ALDH1A1HPGDMAPTALOX12
SCHEMBL28345828 0.61 CYP19A1 (0.50) ALDH1A1HPGDKDM4E
SCHEMBL9664257 0.61 MAPK1 (0.53) ALDH1A1MAPK1HTTKDM4ENPC1
SCHEMBL27420056 0.60 MAPK1 (0.56) ALDH1A1PTGS2MAPK1HTTKDM4E
SCHEMBL30523605 0.60 MAPK1 (0.56) ALDH1A1PTGS2MAPK1HTTKDM4E
SCHEMBL10455225 0.59 PYCR1 (0.39) ALDH1A1MAPTPTGS2NPC1CYP1A2
SCHEMBL17926731 0.58 KDM4E (0.48) ALDH1A1MAPTALOX12MAPK1HTT
SCHEMBL9262964 0.57 L3MBTL1 (0.65) ADORA2AALDH1A1MAPTKDM4EKMT2A
Diphenylacetylene SCHEMBL27594323 0.57 APP (0.60) ALDH1A1HPGDMAPTGRM5HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686345-B2 INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. RESEARCH DEVELOPMENT FOUNDATION 2004-02-03 US disclosed
US-20020132797-A1 DNA-cleaving antitumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132797-A1 DNA-cleaving antitumor agents DNASE1, DNASE1L3, DCLRE1B ADORA3 386/4885ADORA2A 220/4885ADORA1 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.